Brief: SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
06/02/2024 14:43
Feb 6 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS ANNOUNCES PUBLICATION OF PRECLINICAL DATA ON ITS
HIGHLY
SELECTIVE CDK9 INHIBITOR, SLS009, IN ONCOTARGET
Source text for Eikon: ID:nGNX7kZQmm
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses